ATE380807T1 - N-oxid von n-phenyl-2-pyrimidinaminderivaten - Google Patents

N-oxid von n-phenyl-2-pyrimidinaminderivaten

Info

Publication number
ATE380807T1
ATE380807T1 AT03731700T AT03731700T ATE380807T1 AT E380807 T1 ATE380807 T1 AT E380807T1 AT 03731700 T AT03731700 T AT 03731700T AT 03731700 T AT03731700 T AT 03731700T AT E380807 T1 ATE380807 T1 AT E380807T1
Authority
AT
Austria
Prior art keywords
derivatives
phenyl
pyrimidinemin
oxide
preparation
Prior art date
Application number
AT03731700T
Other languages
English (en)
Inventor
Klaus Boernsen
Peter End
Gerhard Gross
Ulrike Pfaar
Juerg Zimmermann
Paul William Manley
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9929594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE380807(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE380807T1 publication Critical patent/ATE380807T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
AT03731700T 2002-01-23 2003-01-22 N-oxid von n-phenyl-2-pyrimidinaminderivaten ATE380807T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0201508.9A GB0201508D0 (en) 2002-01-23 2002-01-23 Organic compounds

Publications (1)

Publication Number Publication Date
ATE380807T1 true ATE380807T1 (de) 2007-12-15

Family

ID=9929594

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03731700T ATE380807T1 (de) 2002-01-23 2003-01-22 N-oxid von n-phenyl-2-pyrimidinaminderivaten

Country Status (15)

Country Link
US (5) US7557105B2 (de)
EP (3) EP1783126A3 (de)
JP (2) JP4213595B2 (de)
KR (2) KR20070058019A (de)
CN (2) CN100467461C (de)
AT (1) ATE380807T1 (de)
BR (1) BR0307058A (de)
CA (1) CA2474104C (de)
DE (1) DE60318013T2 (de)
ES (2) ES2503734T3 (de)
GB (1) GB0201508D0 (de)
IL (2) IL162979A (de)
MX (1) MXPA04007130A (de)
PT (2) PT1470120E (de)
WO (1) WO2003062220A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415987B1 (de) * 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
PL1635835T3 (pl) * 2003-06-13 2010-06-30 Novartis Ag Pochodne 2-aminopirymidyny jako inhibitory kinazy RAF
ATE428421T1 (de) * 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (de) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Testverfahren für die wirkung eines vaskularisierungsinhibitors
CN101316590B (zh) * 2005-11-07 2011-08-03 卫材R&D管理有限公司 血管生成抑制剂和c-kit激酶抑制剂的组合使用
WO2007071752A2 (en) * 2005-12-21 2007-06-28 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
WO2007136103A1 (ja) * 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
BRPI0715634A2 (pt) * 2006-09-01 2013-07-02 Teva Pharma composiÇÕes de imatinibe
US20080207904A1 (en) * 2006-10-26 2008-08-28 Macdonald Peter Imatinib base, and imatinib mesylate and processes for preparation thereof
EP2009008A1 (de) * 2006-10-26 2008-12-31 Sicor, Inc. Imatinib-Base und Imatinib-Mesylat und Herstellungsverfahren dafür
CN101225085B (zh) * 2007-01-17 2011-09-21 天津天士力集团有限公司 苯基呋咱氮类一氧化氮供体型2-苯胺嘧啶衍生物、其制备方法、含有该化合物的组合物及其用途
EP2119707B1 (de) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Zusammensetzung zur behandlung von nicht differenzierten formen von magenkrebsen
CN101245061B (zh) * 2007-02-13 2012-09-19 天津天士力集团有限公司 N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶胺类一氧化氮供体型衍生物，制备方法及其用途
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
EP2152079A4 (de) * 2007-06-04 2011-03-09 Avila Therapeutics Inc Heterocyclische verbindungen und ihre verwendung
JP5710251B2 (ja) 2007-06-07 2015-04-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規ヘテロ環化合物およびその使用
JP5559043B2 (ja) 2007-06-07 2014-07-23 イントラ−セルラー・セラピーズ・インコーポレイテッド 新規ヘテロ環化合物およびその使用
EP2081556A1 (de) * 2007-09-25 2009-07-29 Teva Pharmaceutical Industries Ltd. Stabile zusammensetzungen von imatinib
CN101848895B (zh) * 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
US20100324087A1 (en) * 2008-01-29 2010-12-23 Eisai R&D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
WO2009118108A1 (en) * 2008-03-26 2009-10-01 Merck Patent Gmbh Method of long term storage of substrate-coupled beads
CN101417995B (zh) * 2008-11-21 2012-06-06 陈依军 苯氧基嘧啶衍生物及其制备方法和用途
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
EP2700403B1 (de) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutikum für tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
CN103588754B (zh) * 2013-11-04 2015-05-27 遵义医学院 伊马替尼的制备方法
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
CN107573322A (zh) * 2017-09-06 2018-01-12 南京优科生物医药研究有限公司 伊马替尼双氮氧化物、其制备方法和用途
CN109761970B (zh) * 2019-01-26 2020-06-09 中国药科大学 一种蛋白靶向降解嵌合分子、制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607041A (en) * 1983-04-27 1986-08-19 Fisons Plc Antihypertensive 2-phenyl Hantzsch dihydropyridines
TW225528B (de) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
DE4444288A1 (de) * 1994-12-13 1996-06-20 Rainer Dr Med Etzel Verwendung von Weihrauch zur Behandlung der Alzheimer-Krankheit
EP0812195B1 (de) * 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Arzneizubereitungen für piperidinalkanolderivate
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments

Also Published As

Publication number Publication date
EP1783126A3 (de) 2008-11-26
GB0201508D0 (en) 2002-03-13
DE60318013D1 (de) 2008-01-24
US20090239879A1 (en) 2009-09-24
IL208399A (en) 2013-02-28
MXPA04007130A (es) 2004-10-29
ES2294293T3 (es) 2008-04-01
EP1783126A2 (de) 2007-05-09
CN101468984A (zh) 2009-07-01
EP1470120B1 (de) 2007-12-12
ES2503734T3 (es) 2014-10-07
US7557105B2 (en) 2009-07-07
PT1470120E (pt) 2008-03-03
IL162979A (en) 2010-12-30
JP2009051837A (ja) 2009-03-12
WO2003062220A1 (en) 2003-07-31
EP2194049B1 (de) 2014-08-13
KR20070058019A (ko) 2007-06-07
KR100778163B1 (ko) 2007-11-28
CA2474104A1 (en) 2003-07-31
US20100222362A1 (en) 2010-09-02
JP5027076B2 (ja) 2012-09-19
CN100467461C (zh) 2009-03-11
US20140323494A1 (en) 2014-10-30
KR20040081467A (ko) 2004-09-21
BR0307058A (pt) 2004-12-28
CA2474104C (en) 2012-04-17
EP1470120A1 (de) 2004-10-27
IL208399A0 (en) 2010-12-30
DE60318013T2 (de) 2008-11-13
JP2005519908A (ja) 2005-07-07
EP2194049A1 (de) 2010-06-09
JP4213595B2 (ja) 2009-01-21
US20050209452A1 (en) 2005-09-22
US20110294820A1 (en) 2011-12-01
PT2194049E (pt) 2014-11-10
CN1646519A (zh) 2005-07-27

Similar Documents

Publication Publication Date Title
DE60318013D1 (de) N-oxid von n-phenyl-2-pyrimidinaminderivaten
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
CY1119309T1 (el) Συνδυασμενη χρηση toy (+)-1,4-διϋδρο-7-[(3s,4s)-3-meθoξy-4-(μεθυλαμινο)-1-πυρρολιδινυλ]-4-οξο-1(2-θειαζολυλ)-1,8-ναφθυριδιν-3-καρβοξυλικου οξεος και της κυταραβινης (ara-c) για την αγωγη της λευχαιμιας
IL163090A (en) Nicotinamide derivates, pharmaceutical compositions comprising them and their use for manufacture of medicaments useful as p38 inhibitors
ATE556713T1 (de) Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
BR0308452A (pt) composições farmacêuticas e métodos de preparação de composição farmacêutica
ATE454378T1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
ATE555789T1 (de) Pyridazinderivate und deren verwendung als therapeutische mittel
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
ATE532772T1 (de) Piperazinderivate und deren verwendung als therapeutische mittel
ATE515277T1 (de) Zusammensetzungen und verfahren zum beschichten von medizinischen implantaten
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
TW200510297A (en) Substituted n-aryl heterocycles, process for their preparation and their use as medicaments
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
ATE508114T1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
NO20045056L (no) Fremgangsmater for behandling av hepatitt
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
ATE328879T1 (de) Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE358485T1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
IS6925A (is) Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1470120

Country of ref document: EP